secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020490
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks Q1 revenue $81M, down 52% YoY; Cell Engineering rev up 59%
--------------------------------------------------------------------------

- Q1 2023 total revenue $81M (down 52% YoY); Cell Engineering rev $34M (+59% YoY); Biosecurity rev $47M (52% gross margin).
- Operating loss $(216)M (incl. $75M SBC); Adj. EBITDA $(100)M vs $(1)M prior year. Cash ~$1.2B.
- Added 13 new Cell Programs (18% YoY growth); FY2023 outlook: at least 100 new programs, total rev ≥$275M.
- Acquired StrideBio's AAV capsid engineering platform to advance gene therapy capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/0000950170-23-020490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/dna-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer